Black Diamond Therapeutics $(BDTX)$ and French pharmaceutical group Servier said Wednesday that they have signed a global licensing agreement for Servier to develop and commercialize BDTX-4933, a potential targeted therapy for solid tumors.
Black Diamond will receive a $70 million upfront payment and be eligible for up to $710 million in development and commercial sales milestone payments, and tiered royalties on international net sales, they said.
Shares of Black Diamond soared 23% as intraday trading volume catapulted to more than 100 million shares from a daily average of about 774,000.
Boeing's $(BA)$ Q1 cash outflow will likely be smaller than previously projected due to ongoing stabilization of factory operations and a clearing out of inventory, Chief Financial Officer Brian West said during a Bank of America conference.
Shares of Boeing rose 5.5%, with trading volume of over 10 million shares against daily average of about 8.13 million.
Signet Jewelers $(SIG)$ reported a new strategy to simplify its brand portfolio and accelerate growth. It also issued a fiscal Q1 sales outlook that beat market estimates at the midpoint.
Its shares jumped 17%, with trading volume of more than 3.3 million versus a daily average of about 1.6 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.